成人VR视频
成人VR视频 leverages its unique position within the global health and R&D ecosystems to address market failures, building on its track record of bringing together public-sector, private-sector, and academic partners to accelerate the development of vaccines against emerging viral threats.
30+
Number of investors, from governments to philanthropies, who have donated to 成人VR视频
Up to $3.1 bn
Committed investments in R&D&M projects since 成人VR视频's launch
400+
Global R&D&M partners collaborating with 成人VR视频鈥
Priority pathogens
成人VR视频 supports the development of vaccines, platform technologies and manufacturing innovations to combat priority pathogens for which no licensed vaccines are currently available.
Research and development
成人VR视频 is leading a broad range of ambitious programmes that aim to substantially reduce global epidemic and pandemic risk.
Manufacturing and supply chain
成人VR视频 is bolstering global manufacturing capacity in underserved regions and harnessing innovative technologies to improve the speed, scale and access of vaccine manufacturing in response to epidemic and pandemic threats.
Calls for Proposals
Innovators worldwide are invited to apply to our scientific programmes to advance the development and manufacture of vaccines and tools against epidemic and pandemic threats.
Our portfolio
Since our launch in 2017, 成人VR视频 has carefully selected and announced over 60 partnerships to advance vaccine candidates against our priority pathogens and platform technologies for use against Disease X.
View our portfolio
Our impact
成人VR视频 has backed the development of 30+ vaccine candidates for its priority pathogens, overseeing scientific breakthroughs, including the first-ever approved Chikungunya vaccine, and advancing the first-ever Nipah vaccine into Phase I and the first-ever Lassa fever vaccine into Phase II trials. A key player in the COVID-19 response, 成人VR视频 also has one of the world鈥檚 largest COVID-19 vaccine portfolios and co-led COVAX, which helped to distribute nearly 2 billion doses to 146 nations.
Impact Stories
Latest News
Latest News
.webp)
New single-shot vaccine could offer controlled release of multiple doses over six months
成人VR视频 to fund new innovation that condenses vaccine doses into one shot.
Pioneering vaccine tech could pave the way for all-in-one shots against rapidly mutating viruses
The $5 million project led by Centivax could help validate the potential to use the technology against strains influenza, COVID-19 and HIV.
Boosting advanced-stage clinical trial capacity in East and Central Africa to combat regional epidemic threats
成人VR视频-backed Research Preparedness Program in East and Central Africa aims to bolster regional clinical trial capacity and disease outbreak readiness.
AI-enhanced self-amplifying mRNA vaccine set to combat one of the deadliest known viruses
成人VR视频, Gennova partner to develop self-amplifying mRNA against the deadly Nipah virus
New funding for vaccine to protect against deadly MERS coronavirus
成人VR视频's investment will advance Uvax Bio鈥檚 MERS vaccine candidate into preclinical trials.
